Literature DB >> 20111023

Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.

Olivia M Thompson1, Shirley A A Beresford, Elizabeth A Kirk, Mary P Bronner, Thomas L Vaughan.   

Abstract

Persons diagnosed with Barrett's esophagus (BE) are at increased risk of developing esophageal adenocarcinoma (EA). Obesity is a major risk factor for both BE and EA. The primary purposes of this study were to determine whether circulating levels of leptin and adiponectin, both of which are deregulated in obese states, predict risk of specialized intestinal metaplasia (SIM) occurring in the esophagus (BE) and/or gastroesophageal junction, and evaluate the extent to which they mediate the relationship between obesity and these conditions. In this case-control study, 177 persons newly diagnosed with SIM were compared with 173 general population controls using unconditional logistic regression. Females in the highest tertiles of BMI and waist circumference were at the greatest risk (adjusted odds ratio (OR) = 4.6 (95% confidence interval (CI) = 1.9, 11.6), P(trend) = 0.002; OR = 5.1 (95% CI = 2.0, 13.0), P(trend) = 0.002, respectively) compared to females in the lowest tertiles. Adjustment for leptin and adiponectin attenuated these associations by 52 and 42%, respectively. Males in the highest tertile of waist-to-hip ratio were at the greatest risk (adjusted OR = 2.8 (95% CI = 1.3, 5.9), P(trend) = 0.014) compared to males in the lowest tertile. However, adjustment for leptin and adiponectin did not attenuate these associations. Our study results are consistent with the notion that circulating leptin and adiponectin partially mediate the obesity-BE relationship in women. Leptin and adiponectin's role in the progression from normal epithelium to SIM/BE and on to EA should be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20111023      PMCID: PMC3125020          DOI: 10.1038/oby.2009.508

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  35 in total

Review 1.  Epidemiologic trends in esophageal and gastric cancer in the United States.

Authors:  Linda Morris Brown; Susan S Devesa
Journal:  Surg Oncol Clin N Am       Date:  2002-04       Impact factor: 3.495

2.  Relationship of ghrelin and leptin hormones with body mass index and waist circumference in a random sample of adults.

Authors:  Veronica Monti; Joseph J Carlson; Steven C Hunt; Ted D Adams
Journal:  J Am Diet Assoc       Date:  2006-06

3.  Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights.

Authors:  A M Isidori; F Strollo; M Morè; M Caprio; A Aversa; C Moretti; G Frajese; G Riondino; A Fabbri
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

4.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

5.  Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Authors:  Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-08       Impact factor: 4.254

6.  Leptin and the risk of Barrett's oesophagus.

Authors:  B J Kendall; G A Macdonald; N K Hayward; J B Prins; I Brown; N Walker; N Pandeya; A C Green; P M Webb; D C Whiteman
Journal:  Gut       Date:  2008-01-04       Impact factor: 23.059

7.  Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation.

Authors:  Olorunseun O Ogunwobi; Ian L P Beales
Journal:  Mol Cell Endocrinol       Date:  2008-02-07       Impact factor: 4.102

8.  Abdominal obesity and body mass index as risk factors for Barrett's esophagus.

Authors:  Douglas A Corley; Ai Kubo; Theodore R Levin; Gladys Block; Laurel Habel; Wei Zhao; Pat Leighton; Charles Quesenberry; Greg J Rumore; Patricia A Buffler
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

9.  Population attributable risks of esophageal and gastric cancers.

Authors:  Lawrence S Engel; Wong-Ho Chow; Thomas L Vaughan; Marilie D Gammon; Harvey A Risch; Janet L Stanford; Janet B Schoenberg; Susan T Mayne; Robert Dubrow; Heidrun Rotterdam; A Brian West; Martin Blaser; William J Blot; Mitchell H Gail; Joseph F Fraumeni
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

10.  Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture.

Authors:  Ian L P Beales; Olorunseun O Ogunwobi
Journal:  Mol Cell Endocrinol       Date:  2007-06-02       Impact factor: 4.102

View more
  33 in total

1.  Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus.

Authors:  Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

Review 2.  Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-22       Impact factor: 11.382

3.  Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.

Authors:  Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-15       Impact factor: 11.382

Review 4.  Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis.

Authors:  Apoorva Krishna Chandar; Swapna Devanna; Chang Lu; Siddharth Singh; Katarina Greer; Amitabh Chak; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-15       Impact factor: 11.382

5.  Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.

Authors:  Lucy M Almers; James E Graham; Peter J Havel; Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-26       Impact factor: 11.382

6.  Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data.

Authors:  Jennifer Drahos; Winnie Ricker; Ruth Parsons; Ruth M Pfeiffer; Joan L Warren; Michael B Cook
Journal:  J Clin Gastroenterol       Date:  2015-04       Impact factor: 3.062

7.  Ghrelin and Leptin Have a Complex Relationship with Risk of Barrett's Esophagus.

Authors:  Stuart J Thomas; Lucy Almers; Jennifer Schneider; James E Graham; Peter J Havel; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2015-09-22       Impact factor: 3.199

8.  The risk of Barrett's esophagus associated with abdominal obesity in males and females.

Authors:  Bradley J Kendall; Graeme A Macdonald; Nicholas K Hayward; Johannes B Prins; Suzanne O'Brien; David C Whiteman
Journal:  Int J Cancer       Date:  2012-10-30       Impact factor: 7.396

9.  Association of Barrett's esophagus with type II Diabetes Mellitus: results from a large population-based case-control study.

Authors:  Prasad G Iyer; Bijan J Borah; Herbert C Heien; Ananya Das; Gregory S Cooper; Amitabh Chak
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-13       Impact factor: 11.382

Review 10.  Gastroesophageal reflux and rhinosinusitis.

Authors:  Elin-Johanne Katle; Jan G Hatlebakk; Sverre Steinsvåg
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.